LabGenomics
Key metrics
Earnings
| Revenue, Q3 2026 | ₩13.7bn |
|---|---|
| Revenue QoQ | -13.3% |
| Revenue YoY | -40.7% |
| Operating income, Q3 2026 | -₩3.5bn |
| Operating income QoQ | +49.6% |
| Operating income YoY | -63.6% |
Share buybacks
| Buyback decided, last 3 months | ₩1.0bn |
|---|---|
| Buyback decided, last 3 months, % of shares | 4.1% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩1.0bn |
| Buyback decided, last 12 months, % of shares | 4.1% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩20.0bn |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 17,050,298 shares |
| Potential new shares, % of shares | 114.8% |
| Conversion price adjustments, last 12 months | 1 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 9 |
|---|---|
| DART filings, previous 3 months | 17 |
Insider transactions
| Open-market buys, last 12 months (shares) | 3,133,991 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩3.0bn |
| Open-market sells, last 12 months (shares) | 28,968 shares |
| Open-market sells, last 12 months (amount) | ₩42m |
| Net open-market buying, last 12 months (shares) | 3,105,023 shares |
| Insiders who bought, last 12 months | 1 |
Insider transactions (last 12 months)
Open-market buys: 3,133,991 shares (₩3.0bn). Open-market sells: 28,968 shares (₩42m). Net open-market buying: +3,105,023 shares. Insiders who bought: 1.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Other (Reverse split) | -12,106,820 shares | — | — | |
| Sep 2, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Other (Reverse split) | -5,862,953 shares | — | — | |
| Sep 2, 2026 | Lee Jong-hun (Registered director) | Other (Reverse split) | -69,874 shares | — | — | |
| Sep 2, 2026 | Chae Yeong-hwan (Non-registered officer) | Other (Reverse split) | -22,888 shares | — | — | |
| Sep 2, 2026 | Oh Mi-jin (Non-registered officer) | Other (Reverse split) | -24,096 shares | — | — | |
| Jul 9, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Open-market buy | +970,100 shares | ₩845 | ₩820m | |
| Jul 8, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Open-market buy | +270,000 shares | ₩668 | ₩180m | |
| Jun 10, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Open-market buy | +679,453 shares | ₩1,268 | ₩862m | |
| Jun 9, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Open-market buy | +432,692 shares | ₩1,061 | ₩459m | |
| Jun 8, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Open-market buy | +781,746 shares | ₩869 | ₩679m | |
| May 20, 2026 | Oh Mi-jin (Non-registered officer) | Open-market sell | -28,968 shares | ₩1,455 | ₩42m | |
| May 18, 2026 | Ruhagalraktikoseuyuhanhoesa (10%+ shareholder) | Other | -7,328,692 shares | — | — |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩88.2bn | -₩53.5bn |
| 2024 | ₩85.9bn | -₩18.5bn |
| 2023 | ₩73.1bn | -₩6.8bn |
Filing timeline
-
LabGenomics plans ₩1.0bn share buyback of 613,496 shares
LabGenomics plans to buy back 613,496 shares for ₩1.0bn through direct acquisition on the KOSDAQ market. The buyback period runs from Oct 26, 2026 to Jan 22, 2027. By our calculation, the planned amount is 1.1% of FY2025 revenue.